Breaking News
October 20, 2018 - Antidepressant treatment may lead to improvements in sleep quality of patients with depression
October 20, 2018 - Study reports increased risk of death in children with inflammatory bowel disease
October 20, 2018 - Number of Autism Genes Now Tops 100
October 20, 2018 - Total diet replacement programmes are effective for treating obesity
October 20, 2018 - CLARIOstar used for fluorescence measurements on CSIRO’s purpose-built research vessel
October 20, 2018 - People with more copies of AMY1 gene digest starchy carbohydrates faster
October 20, 2018 - Case Comprehensive Cancer Center wins NIH grant to study health disparities
October 20, 2018 - Newly discovered compound shows potential for treating Parkinson’s disease
October 20, 2018 - High rate of non-adherence to hormonal therapy found among premenopausal early breast cancer patients
October 20, 2018 - Immunotherapy medicine found to be effective in treating uveitis
October 20, 2018 - The Pistoia Alliance Calls for Greater Collaboration to Realise Benefits of Innovation and Announces Winners of the 2018 President’s Startup Challenge
October 20, 2018 - Female internists consistently earn less than men
October 20, 2018 - Stanford team looks at dangers of teens’ vaping habits
October 20, 2018 - New approach to understanding cancers will accelerate development of better treatments
October 20, 2018 - LJI and UC San Diego awarded $ 4.5 million as part of NCI’s Cancer Moonshot initiative
October 20, 2018 - School-based HPV vaccination did not increase risky sexual behaviors among adolescent girls
October 20, 2018 - Eye discovery to pave way for more successful corneal transplants
October 20, 2018 - New analysis examines the importance of location in the opioid crisis
October 20, 2018 - Green filters increase reading speed for children with dyslexia
October 19, 2018 - Bariatric Sx Cuts Macrovascular Complications in Obesity, T2DM
October 19, 2018 - Better assessments for early age-related macular degeneration
October 19, 2018 - Visible and valued: Stanford Medicine’s first-ever LGBTQ+ Forum | News Center
October 19, 2018 - Understanding of metal-free enzymes used by bacteria could lead to new effective antibiotics
October 19, 2018 - Beckman Coulter Life Sciences announces new research-focused website
October 19, 2018 - Study finds link between refined soluble fibers, gut microbiota and liver cancer
October 19, 2018 - Social media reduces risk of depression among seniors with pain
October 19, 2018 - Newly developed synthetic DNA molecule may one day be used as ‘vaccine’ for prostate cancer
October 19, 2018 - Preoperative weight loss may not provide health benefits after surgery
October 19, 2018 - U.S. Birth Rates Continue to Drop as Age of New Moms Rises
October 19, 2018 - New technology can keep an eye on babies’ movements in the womb
October 19, 2018 - Juul e-cigarettes pose addiction risk for young users | News Center
October 19, 2018 - Gene sequencing reveals crucial molecular aspects of Trypanosoma brucei
October 19, 2018 - New DNA vaccine strategy protects mice against lethal challenge by multiple H3N2 viruses
October 19, 2018 - Study shows close link between cytokine interleukin-1ß and obesity-promoted colon cancer
October 19, 2018 - Muscle mass plays a critical role in health, shows research
October 19, 2018 - Study finds undiagnosed prediabetes in many infertile men
October 19, 2018 - The Current issue of “The view from here” is concerned with Nanotherapeutic strategies
October 19, 2018 - Delay in replacing the Pap smear with HPV screening is costing lives
October 19, 2018 - Physicians battle pediatric diseases of ear, nose, throat in Zimbabwe | News Center
October 19, 2018 - Researchers investigate why some cancers affect only young women
October 19, 2018 - Drugmakers funnel millions to lawmakers; a few dozen get $100,000-plus
October 19, 2018 - Unselfish people tend to have more children and receive higher salaries
October 19, 2018 - New findings reveal potential cellular players in tumor microenvironment
October 19, 2018 - Some countries take more time for reimbursement decisions on new cancer drugs
October 19, 2018 - Human brain cell transplant offers insights into neurological conditions
October 19, 2018 - Parental education associated with increased family health care spending
October 19, 2018 - New statistical method estimates long- and short-term risk of recurrence of breast cancer in US women
October 19, 2018 - Father’s exposure to nicotine may cause cognitive deficits in descendants
October 19, 2018 - Could we prevent Alzheimer’s disease by treating herpes?
October 19, 2018 - Nurse-led care can be more successful in managing gout
October 19, 2018 - Trump administration, pharma exchange verbal volleys on drug-price transparency
October 19, 2018 - Duke researchers find way to detect blood doping in athletes
October 19, 2018 - Many primary care doctors are still prescribing sedative drugs for older adults
October 19, 2018 - Finger length can predict sexuality in women say researchers
October 19, 2018 - Study finds differences in side-effects experienced by male and female OG cancer patients
October 19, 2018 - Dysfunction of single gene leads to miscarriages
October 19, 2018 - Few Seniors Who Self-Harm Referred for Mental Health Care
October 19, 2018 - Don’t sweat the sweet stuff
October 19, 2018 - URMC researchers discover new approach to deliver therapeutics to the brain
October 19, 2018 - Speech Pathology Australia raises awareness about Developmental Language Disorder
October 19, 2018 - Middlemen suppliers can increase drug prices and hospital bills, say Johns Hopkins researchers
October 19, 2018 - Survey finds high prevalence of HTLV-1 infection among teens and adults in Gabon
October 19, 2018 - Bliss funds research to find whether parental touch can help alleviate pain in premature infants
October 19, 2018 - Human neurons employ highly compartmentalized signaling, study shows
October 19, 2018 - Ultromics expands multiple clinical trials for coronary heart disease to the U.S.
October 19, 2018 - $11 million NIH grant for Clemson University helps launch new center for musculoskeletal research
October 19, 2018 - A new approach identified to control Zika virus, dengue fever
October 19, 2018 - Head Blows Without Concussion May Not Damage Brain, Study Claims
October 19, 2018 - US opioid use not declined, despite focus on abuse and awareness of risk
October 19, 2018 - Next-generation RNA sequencing technology sheds new light on human mitochondrial diseases
October 19, 2018 - UT Southwestern biochemist receives 2019 Breakthrough Prize in Life Sciences for innate immunity discovery
October 19, 2018 - The immune system also plays a key role in day-to-day function of healthy organs
October 19, 2018 - New tool may reveal how the brain structure impacts brain activity, human behavior
October 19, 2018 - Trump Administration announces ‘Winning on Reducing Food Waste’ initiative
October 19, 2018 - For-profit nursing home residents more likely to experience health issues caused by substandard care
October 19, 2018 - Incidence of stroke has risen steadily among marijuana users, show studies
October 19, 2018 - Conceptual framework proposed to examine role of exercise in multiple sclerosis
October 19, 2018 - Near infrared spectroscopy technique for accurate evaluation of chondral injuries
October 19, 2018 - Scientists receive $5.1 million grant to develop stem cell-based therapy for blinding retinal conditions
October 19, 2018 - Shorter physician encounters associated with antibiotic prescribing
Tocilizumab Benefits Persist in SSc

Tocilizumab Benefits Persist in SSc

image_pdfDownload PDFimage_print

Action Points

  • Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial.
  • The most common adverse events in this study were infections, as has been seen in clinical trials of tocilizumab in rheumatoid arthritis.

Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial, researchers reported.

At week 48, the conclusion of the double-blind phase of a study known as faSScinate, change from baseline on the modified Rodnan skin score was -5.6 (95% CI -8.9 to -2.4) among patients who were receiving tocilizumab, according to Dinesh Khanna, MD, of the University of Michigan in Ann Arbor, and colleagues.

By week 96, additional decreases were seen on skin scores, bringing the total improvement to a score of -9.1 (95% CI -12.5 to -5.6).

Meanwhile, patients who had been randomized to placebo for the first 48 weeks had a change from baseline in Rodnan skin scores of -3.1 (95% CI -5.4 to -0.9), but by week 96, after 48 weeks of open-label tocilizumab, mean change in score was -9.4 (95% CI -11.8 to -7), the investigators reported online in Annals of the Rheumatic Diseases.

The differences at week 48, while clinically meaningful, were not statistically significant, they noted.

Morbidity and mortality are high among patients with systemic sclerosis, particularly among those with lung involvement, and few treatment options are available. Cyclophosphamide has been used for pulmonary disease, but is associated with significant toxicity, and stem cell transplantation has improved skin fibrosis and lung function but is associated with risks and high costs.

The rationale for using tocilizumab, a monoclonal antibody targeting the interleukin (IL)-6 receptor-α, is that IL-6 is thought to be involved in the pathogenesis of SSc, with patients having increased IL-6 expression in endothelial cells and elevations of IL-6 in serum.

The faSScinate study was conducted in 35 centers in North America and Europe, enrolling 87 patients with active disease of less than 5 years’ duration. The majority were white women, and baseline total modified Rodnan skin score was about 25. The treatment consisted of subcutaneous injections of tocilizumab, 162 mg, once weekly.

At week 48, 30 (69.8%) of the patients originally randomized to tocilizumab entered the open-label phase, as did 31 (70.5%) of those who received placebo in the blinded phase. The full 96-week study was completed by 27 (62.8%) of those who had been on active treatment throughout and by 24 (54.5%) of those originally given placebo.

By week 96, a total of 27 patients who had been on continuous tocilizumab (during the placebo-controlled phase and the open-label phase) had achieved the minimal clinically important difference on the skin score of a change of at least 4.7 units, as had 24 of those in the placebo-tocilizumab group.

For lung function, similar proportions of patients in the continuous tocilizumab and placebo-tocilizumab experienced absolute decreases in percent predicted forced vital capacity in the open-label phase (46% and 42%, respectively), whereas during the double-blind phase, 54% of the tocilizumab group experienced any worsening compared with 83% of those in the placebo group.

Improvements also were seen on patient-reported outcomes by week 96 for both continuous tocilizumab and placebo-tocilizumab groups. For instance, on the Health Assessment Questionnaire Disability Index, changes from baseline were -0.13 and -0.29, respectively.

The most common adverse events in this study were infections, as has been seen in clinical trials of tocilizumab in rheumatoid arthritis. However, “rates of serious adverse events and serious infections in this study in patients with SSc were approximately five times and eight times higher, respectively, than those reported in patients with rheumatoid arthritis, which is expected given the high morbidity and mortality in patients with SSc,” the authors wrote.

In particular, patients with SSc are prone to develop digital ulcers, and two patients had infected digital ulcers and one had osteomyelitis.

The investigators emphasized that the study was not powered for a statistical comparison of efficacy during the open-label phase, noting that a phase III randomized controlled trial (NCT02453256) including more than 200 patients is underway.

They concluded that tocilizumab was beneficial for skin and lung manifestations of SSc, and “may be a promising targeted therapy for patients with progressive SSc who have few treatment options.”

Limitations of the study were its open-label design after week 48 and a high discontinuation rate. In addition, patients who completed the 48-week blinded phase and entered the open-label phase may have been healthier, so selection bias was possible.

The study was funded by Roche.

The authors reported financial relationships with Roche, Actelion, Boehringer-Ingelheim, Covis, CSL Behring, Corbus, Cytori, EMD Serono, Genentech/Roche, GlaxoSmithKline, Inventiva, Medac, Sanofi-Aventis, UCB, Bristol-Myers Squibb, Bayer, Pfizer, Eicos Sciences, AstraZeneca, Eli Lilly, Galapagos, Servier, Sandoz, and Chugai. Several are employees of Roche or Genentech.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2017-10-25T14:30:00-0400

Tagged with:

About author

Related Articles